SPYRE THERAPEUTICS, INC. Research and Development Expense (Excluding Acquired in Process Cost)
SPYRE THERAPEUTICS, INC. (SYRE) reported Research and Development Expense (Excluding Acquired in Process Cost) of $65.50 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost · last filed 2026-08-04
- SPYRE THERAPEUTICS, INC. research and development expense (excluding acquired in process cost) for the quarter ending 2026-06-30 was $65.50M, a 63.17% increase year-over-year.
- SPYRE THERAPEUTICS, INC. research and development expense (excluding acquired in process cost) for the quarter ending 2026-03-31 was $60.41M, a 45.14% increase year-over-year.
- SPYRE THERAPEUTICS, INC. research and development expense (excluding acquired in process cost) for the quarter ending 2025-12-31 was $44.64M, a 11.58% decline year-over-year.
- SPYRE THERAPEUTICS, INC. research and development expense (excluding acquired in process cost) for the quarter ending 2025-09-30 was $45.25M, a 1.12% increase year-over-year.
- SPYRE THERAPEUTICS, INC. research and development expense (excluding acquired in process cost) for fiscal 2025 was $171.65M, a 5.44% increase from fiscal 2024.
- SPYRE THERAPEUTICS, INC. research and development expense (excluding acquired in process cost) for fiscal 2024 was $162.79M, a 81.88% increase from fiscal 2023.
- SPYRE THERAPEUTICS, INC. research and development expense (excluding acquired in process cost) for fiscal 2023 was $89.50M, a 52.79% increase from fiscal 2022.
- SPYRE THERAPEUTICS, INC. research and development expense (excluding acquired in process cost) for fiscal 2022 was $58.58M, a 2.65% increase from fiscal 2021.
| Period end | Research and Development Expense (Excluding Acquired in Process Cost) 3 month | Research and Development Expense (Excluding Acquired in Process Cost) 6 month | Research and Development Expense (Excluding Acquired in Process Cost) 9 month | Research and Development Expense (Excluding Acquired in Process Cost) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $65.50M 10-Q · filed 2026-08-04 | $125.91M 10-Q · filed 2026-08-04 | $170.55M derived: sum of 3 quarters · filed 2026-08-04 | $215.80M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $60.41M 10-Q · filed 2026-05-05 | $105.05M derived: sum of 2 quarters · filed 2026-05-05 | $150.30M derived: sum of 3 quarters · filed 2026-05-05 | $190.44M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $44.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $89.89M derived: sum of 2 quarters · filed 2026-02-19 | $130.03M derived: sum of 3 quarters · filed 2026-08-04 | $171.65M 10-K · filed 2026-02-19 |
| 2025-09-30 | $45.25M 10-Q · filed 2025-11-04 | $85.39M derived: sum of 2 quarters · filed 2026-08-04 | $127.02M 10-Q · filed 2025-11-04 | $177.50M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $40.15M 10-Q · filed 2026-08-04 | $81.77M 10-Q · filed 2026-08-04 | $132.25M derived: sum of 3 quarters · filed 2026-08-04 | $176.99M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $41.62M 10-Q · filed 2026-05-05 | $92.11M derived: sum of 2 quarters · filed 2026-05-05 | $136.85M derived: sum of 3 quarters · filed 2026-05-05 | $169.49M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $50.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $95.23M derived: sum of 2 quarters · filed 2026-02-19 | $127.86M derived: sum of 3 quarters · filed 2026-02-19 | $162.79M 10-K · filed 2026-02-19 |
| 2024-09-30 | $44.74M 10-Q · filed 2025-11-04 | $77.38M derived: sum of 2 quarters · filed 2025-11-04 | $112.31M 10-Q · filed 2025-11-04 | $145.99M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $32.64M 10-Q · filed 2025-08-05 | $67.56M 10-Q · filed 2025-08-05 | $101.25M derived: sum of 3 quarters · filed 2026-02-19 | $125.91M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $34.93M 10-Q · filed 2025-05-08 | $68.61M derived: sum of 2 quarters · filed 2026-02-19 | $93.27M derived: sum of 3 quarters · filed 2026-02-19 | $110.66M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $33.68M derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-02-19 | $58.34M derived: sum of 2 quarters · filed 2026-02-19 | $75.73M derived: sum of 3 quarters · filed 2026-02-19 | $89.50M 10-K · filed 2026-02-19 |
| 2023-09-30 | $24.66M 10-Q/A · filed 2024-11-18 | $42.05M derived: sum of 2 quarters · filed 2024-11-18 | $55.82M 10-Q/A · filed 2024-11-18 | $70.07M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $17.39M 10-Q/A · filed 2024-11-18 | $31.16M 10-Q/A · filed 2024-11-18 | $45.41M derived: sum of 3 quarters · filed 2025-02-27 | $57.39M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $13.78M 10-Q/A · filed 2024-11-18 | $28.03M derived: sum of 2 quarters · filed 2025-02-27 | $40.00M derived: sum of 3 quarters · filed 2025-02-27 | $55.38M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $14.25M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $26.23M derived: sum of 2 quarters · filed 2025-02-27 | $41.60M derived: sum of 3 quarters · filed 2025-02-27 | $58.58M 10-K · filed 2025-02-27 |
| 2022-09-30 | $11.98M 10-Q · filed 2023-11-09 | $27.35M derived: sum of 2 quarters · filed 2023-11-09 | $44.33M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $15.37M 10-Q · filed 2023-08-11 | $32.35M 10-Q · filed 2023-08-11 | ||
| 2021-12-31 | $57.07M 10-K/A · filed 2024-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |